Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaboPen
2017-001963-19Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in penile squamous cell carcinoma (PSCC) and penile neoplasm, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Objective response rate. Started Jun 2021; status: terminated.
02
Drugs
cabozantinib
03
Conditions
penile squamous cell carcinoma (PSCC)penile neoplasm
Beyond the preview
Go deeper on 2017-001963-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001963-19.